Literature DB >> 10559361

Single-step conversion of cells to retrovirus vector producers with herpes simplex virus-Epstein-Barr virus hybrid amplicons.

M Sena-Esteves1, Y Saeki, S M Camp, E A Chiocca, X O Breakefield.   

Abstract

We report here on the development and characterization of a novel herpes simplex virus type 1 (HSV-1) amplicon-based vector system which takes advantage of the host range and retention properties of HSV-Epstein-Barr virus (EBV) hybrid amplicons to efficiently convert cells to retrovirus vector producer cells after single-step transduction. The retrovirus genes gag-pol and env (GPE) and retroviral vector sequences were modified to minimize sequence overlap and cloned into an HSV-EBV hybrid amplicon. Retrovirus expression cassettes were used to generate the HSV-EBV-retrovirus hybrid vectors, HERE and HERA, which code for the ecotropic and the amphotropic envelopes, respectively. Retrovirus vector sequences encoding lacZ were cloned downstream from the GPE expression unit. Transfection of 293T/17 cells with amplicon plasmids yielded retrovirus titers between 10(6) and 10(7) transducing units/ml, while infection of the same cells with amplicon vectors generated maximum titers 1 order of magnitude lower. Retrovirus titers were dependent on the extent of transduction by amplicon vectors for the same cell line, but different cell lines displayed varying capacities to produce retrovirus vectors even at the same transduction efficiencies. Infection of human and dog primary gliomas with this system resulted in the production of retrovirus vectors for more than 1 week and the long-term retention and increase in transgene activity over time in these cell populations. Although the efficiency of this system still has to be determined in vivo, many applications are foreseeable for this approach to gene delivery.

Entities:  

Mesh:

Year:  1999        PMID: 10559361      PMCID: PMC113098     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  63 in total

1.  Construction of retroviral vectors with improved safety, gene expression, and versatility.

Authors:  S H Kim; S S Yu; J S Park; P D Robbins; C S An; S Kim
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

2.  Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector.

Authors:  M Feng; W H Jackson; C K Goldman; C Rancourt; M Wang; S K Dusing; G Siegal; D T Curiel
Journal:  Nat Biotechnol       Date:  1997-09       Impact factor: 54.908

Review 3.  Benefits and risks of hosting animal cells in the human brain.

Authors:  O Isacson; X O Breakefield
Journal:  Nat Med       Date:  1997-09       Impact factor: 53.440

4.  VSV-G-pseudotyped retroviral packaging through adenovirus-mediated inducible gene expression.

Authors:  Y Yoshida; N Emi; H Hamada
Journal:  Biochem Biophys Res Commun       Date:  1997-03-17       Impact factor: 3.575

5.  In vivo retrovirus-mediated gene transfer into multiple hematopoietic lineages in rabbits without preconditioning.

Authors:  D M Nelson; M E Metzger; R E Donahue; R A Morgan
Journal:  Hum Gene Ther       Date:  1997-04-10       Impact factor: 5.695

6.  The herpes simplex virus amplicon: a new eucaryotic defective-virus cloning-amplifying vector.

Authors:  R R Spaete; N Frenkel
Journal:  Cell       Date:  1982-08       Impact factor: 41.582

7.  Defective herpes simplex virus type 1 vectors harboring gag, pol, and env genes can be used to rescue defective retrovirus vectors.

Authors:  N Savard; F L Cosset; A L Epstein
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

8.  Lentiviral vectors for gene therapy of cystic fibrosis.

Authors:  M J Goldman; P S Lee; J S Yang; J M Wilson
Journal:  Hum Gene Ther       Date:  1997-12-10       Impact factor: 5.695

9.  Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells.

Authors:  Z Ram; K W Culver; E M Oshiro; J J Viola; H L DeVroom; E Otto; Z Long; Y Chiang; G J McGarrity; L M Muul; D Katz; R M Blaese; E H Oldfield
Journal:  Nat Med       Date:  1997-12       Impact factor: 53.440

10.  The 9L rat brain tumor: description and application of an animal model.

Authors:  M Weizsaecker; D F Deen; M L Rosenblum; T Hoshino; P H Gutin; M Barker
Journal:  J Neurol       Date:  1981       Impact factor: 4.849

View more
  27 in total

Review 1.  HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part II. Vector systems and applications.

Authors:  A Jacobs; X O Breakefield; C Fraefel
Journal:  Neoplasia       Date:  1999-11       Impact factor: 5.715

2.  Efficient site-specific integration of large transgenes by an enhanced herpes simplex virus/adeno-associated virus hybrid amplicon vector.

Authors:  Qiang Liu; Claudio F Perez; Yaming Wang
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

3.  Targeted signal-amplifying enzymes enhance MRI of EGFR expression in an orthotopic model of human glioma.

Authors:  Mohammed S Shazeeb; Christopher H Sotak; Michael DeLeo; Alexei Bogdanov
Journal:  Cancer Res       Date:  2011-01-18       Impact factor: 12.701

4.  The nucleocapsid domain of Gag is dispensable for actin incorporation into HIV-1 and for association of viral budding sites with cortical F-actin.

Authors:  Sarah Stauffer; Sheikh Abdul Rahman; Alex de Marco; Lars-Anders Carlson; Bärbel Glass; Heike Oberwinkler; Nikolas Herold; John A G Briggs; Barbara Müller; Kay Grünewald; Hans-Georg Kräusslich
Journal:  J Virol       Date:  2014-04-30       Impact factor: 5.103

5.  Plasmid DNA sequences present in conventional herpes simplex virus amplicon vectors cause rapid transgene silencing by forming inactive chromatin.

Authors:  Masataka Suzuki; Kazue Kasai; Yoshinaga Saeki
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

6.  Herpes simplex virus type 1/adeno-associated virus hybrid vectors.

Authors:  Anna Paula de Oliveira; Cornel Fraefel
Journal:  Open Virol J       Date:  2010-06-18

7.  Peroxisome proliferator-activated receptor-gamma regulates the expression and function of very-low-density lipoprotein receptor.

Authors:  Huan Tao; Srikanth Aakula; Naji N Abumrad; Tahar Hajri
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-10-27       Impact factor: 4.310

8.  ICP0 inhibits the decrease of HSV amplicon-mediated transgene expression.

Authors:  Masataka Suzuki; Kazue Kasai; Akihiro Ohtsuki; Jakub Godlewski; Michal O Nowicki; E Antonio Chiocca; Yoshinaga Saeki
Journal:  Mol Ther       Date:  2009-02-17       Impact factor: 11.454

9.  Methods, potentials, and limitations of gene delivery to regenerate central nervous system cells.

Authors:  Arvind Kumar; Tryambak D Singh; Santosh K Singh; Satya Prakash
Journal:  Biologics       Date:  2009-07-13

10.  Herpes Virus Amplicon Vectors.

Authors:  Suresh de Silva; William J Bowers
Journal:  Viruses       Date:  2009-12-01       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.